Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Suvecaltamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I known ✓ | Q9P0X4 | 6/20 | 1.00 |
| ▸ | CACNA1H known ✓ | O95180 | 6/20 | 1.00 |
| ▸ | CACNA1G known ✓ | O43497 | 4/20 | 1.00 |
| ▸ | CNR2 | P34972 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suvecaltamide SCHEMBL29791943 | 1.00 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| Suvecaltamide SCHEMBL21828396 | 1.00 | CACNA1I (1.00) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1064366 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1058794 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL8231358 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL8231799 | 0.91 | CACNA1I (0.83) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1060457 | 0.90 | CACNA1I (0.82) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1060490 | 0.89 | CACNA1I (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1062188 | 0.89 | CACNA1I (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 | |
| SCHEMBL1062749 | 0.89 | CNR2 (0.80) | CACNA1ICACNA1HCACNA1GCNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312323-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. | 2025-10-09 | — | — | US | claimed |
| US-12383539-B2 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CAVION, INC. (US) | 2025-08-12 | — | — | US | claimed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | claimed |
| EP-3615010-B1 | METHODS FOR TREATING DRAVET SYNDROME | CAVION INC (US) | 2024-08-21 | — | — | EP | claimed |
| US-20240238261-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CAVION, INC. | 2024-07-18 | — | — | US | claimed |
| EP-4346817-A1 | METHOD OF TREATING ESSENTIAL TREMOR | Cavion, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| CN-117693342-A | Method for treating essential tremor | 卡维昂公司 | 2024-03-12 | — | — | CN | claimed |
| CN-110770221-B | Methods for improving memory and cognition and for treating memory and cognition disorders | 卡维昂公司 | 2023-09-08 | — | — | CN | claimed |
| WO-2022251812-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CAVION, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| US-20220354834-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-11-10 | — | — | US | claimed |
| EP-3364993-B1 | METHODS FOR TREATING ANGELMAN SYNDROME | CAVION INC (US) | 2022-11-09 | — | — | EP | claimed |
| EP-4041225-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | Cavion, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CAVION, INC. (US) | 2022-05-10 | — | — | US | claimed |
| US-11311522-B1 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CAVION, INC. (US) | 2022-04-26 | — | — | US | claimed |
| US-11273218-B2 | Methods for treating Angelman syndrome and related disorders | CAVION, INC. (US) | 2022-03-15 | — | — | US | claimed |
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | claimed |
| US-8263627-B2 | Pyridyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | claimed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | claimed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | claimed |
| US-12606546-B2 | Small molecule inhibitors of calcium channel activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| US-12486257-B2 | Small molecule inhibitors of CaV3.2 activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250312323-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250312323-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250312323-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250295646-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12383539-B2 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CAVION, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12383539-B2 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CAVION, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-120082611-A | Mutant of aminotransferase and application thereof | 上海合全药业股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4522271-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119584962-A | Methods of using T-type calcium channel modulators | 普拉西斯精密医药公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-117338790-B | Application of buxine alkaloids Buxusemine H and Buxusemine L in pharmacy | 中国科学院昆明植物研究所 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024218288-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218290-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218285-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-17 | — | — | US | disclosed |
| WO-2023220084-A9 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-3615010-B1 | METHODS FOR TREATING DRAVET SYNDROME | CAVION INC (US) | 2024-08-21 | — | — | EP | disclosed |
| JP-2024102139-A | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | カビオン・インコーポレイテッド | 2024-07-30 | — | — | JP | disclosed |
| US-20240238261-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CAVION, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238261-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CAVION, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| JP-2024519390-A | — | カビオン・インコーポレイテッド | 2024-05-10 | — | — | JP | disclosed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | H. LUNDBECK A/S (DK) | 2024-04-16 | — | — | US | disclosed |
| EP-4346817-A1 | METHOD OF TREATING ESSENTIAL TREMOR | Cavion, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4346817-A1 | METHOD OF TREATING ESSENTIAL TREMOR | Cavion, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024056775-A1 | MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-03-21 | — | — | WO | disclosed |
| CN-117693342-A | Method for treating essential tremor | 卡维昂公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117693342-A | Method for treating essential tremor | 卡维昂公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117338790-A | Application of buxus alkaloids Buxusemine H and Buxusemine L in pharmacy | 中国科学院昆明植物研究所 | 2024-01-05 | — | — | CN | disclosed |
| CN-117230129-A | Method for preparing chiral arylamine compound by using aminotransferase or mutant thereof | 上海合全药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230365544-A1 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH | 2023-11-16 | — | — | US | disclosed |
| WO-2023220084-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-116917289-A | T-type calcium channel antagonists and uses thereof | 小利兰·斯坦福大学董事会 | 2023-10-20 | — | — | CN | disclosed |
| CN-110770221-B | Methods for improving memory and cognition and for treating memory and cognition disorders | 卡维昂公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-06-22 | — | — | US | disclosed |
| US-20230165847-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| CN-115776894-A | Methods of use of T-type calcium channel modulators | 普拉西斯精密医药公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4142764-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022216386-A9 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-01 | — | — | WO | disclosed |
| JP-2022550450-A | — | カビオン・インコーポレイテッド | 2022-12-01 | — | — | JP | disclosed |
| WO-2022251812-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CAVION, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022251812-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CAVION, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220354834-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-11-10 | — | — | US | disclosed |
| US-20220354834-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2022-11-10 | — | — | US | disclosed |
| EP-3364993-B1 | METHODS FOR TREATING ANGELMAN SYNDROME | CAVION INC (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2022217248-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022216386-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-4041225-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | Cavion, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4041225-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | Cavion, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114760998-A | Methods and materials for treating neurotoxicity | 卡维昂公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3860571-A4 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | Cavion, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-111056935-B | Dearomatized isopentenyl acyl phloroglucinol derivative, pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2022-05-20 | — | — | CN | disclosed |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CAVION, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CAVION, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11311522-B1 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CAVION, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311522-B1 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CAVION, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11311522-B1 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CAVION, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11273218-B2 | Methods for treating Angelman syndrome and related disorders | CAVION, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11273218-B2 | Methods for treating Angelman syndrome and related disorders | CAVION, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220016095-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220016095-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. | 2022-01-20 | — | — | US | disclosed |
| JP-2022504182-A | — | カビオン・インコーポレイテッド | 2022-01-13 | — | — | JP | disclosed |
| EP-3860571-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | Cavion, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113164393-A | Treatment of essential tremor using (R) -2- (4-isopropylphenyl) -N- (1- (5- (2,2, 2-trifluoroethoxy) pyridin-2-yl) ethyl) acetamide | 卡维昂公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113164393-A | Treatment of essential tremor using (R) -2- (4-isopropylphenyl) -N- (1- (5- (2,2, 2-trifluoroethoxy) pyridin-2-yl) ethyl) acetamide | 卡维昂公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021067697-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | CAVION, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020072773-A9 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020072773-A9 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020072773-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CAVION, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8263627-B2 | Pyridyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263627-B2 | Pyridyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1H 2/4885CACNA1G 1/4885 |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | CACNA1G, CACNA1H, CACNB2 | CACNA1I 7/4885CACNA1H 2/4885CACNA1G 1/4885 |
| US-20220354834-A1 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | CACNA1G, CACNA1I, ATP2A1 | CACNA1I 2/4885CACNA1H 6/4885CACNA1G 1/4885 |
| US-20250295646-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1H 2/4885CACNA1G 1/4885 |
| US-20240238261-A1 | METHOD OF TREATING ESSENTIAL TREMOR | CHAT, ACHE, SLC18A3 | CACNA1I 59/4885CACNA1H 68/4885CACNA1G 82/4885 |
| US-20230365544-A1 | SMALL MOLECULE INHIBITORS OF CALCIUM CHANNEL ACTIVITY AND USES THEREOF | CACNA1G, CACNA1I, CACNG3 | CACNA1I 2/4885CACNA1H 6/4885CACNA1G 1/4885 |
| US-12606546-B2 | Small molecule inhibitors of calcium channel activity and uses thereof | CACNA1G, CACNA1I, CACNA1D | CACNA1I 2/4885CACNA1H 6/4885CACNA1G 1/4885 |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1H 2/4885CACNA1G 1/4885 |
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | LRRK2, PARK7, PINK1 | CACNA1I 4480/4885CACNA1H 4655/4885CACNA1G 4573/4885 |
| US-12486257-B2 | Small molecule inhibitors of CaV3.2 activity and uses thereof | CACNA1B, CACNG3, CACNA1C | CACNA1I 7/4885CACNA1H 17/4885CACNA1G 11/4885 |
| US-12383539-B2 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-Trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CACNA1G, CHRNA3, CACNA1H | CACNA1I 5/4885CACNA1H 3/4885CACNA1G 1/4885 |
| US-11273218-B2 | Methods for treating Angelman syndrome and related disorders | CACNA1G, CACNA1I, CACNA1H | CACNA1I 2/4885CACNA1H 3/4885CACNA1G 1/4885 |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | LRRK2, PARK7, PINK1 | CACNA1I 4480/4885CACNA1H 4655/4885CACNA1G 4573/4885 |
| US-20250312323-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CACNA1G, CHRNA3, CACNA1H | CACNA1I 5/4885CACNA1H 3/4885CACNA1G 1/4885 |
| US-11324733-B2 | Methods for improving memory and cognition and for treating memory and cognitive disorders | CACNA1G, CACNA1I, CACNA1H | CACNA1I 2/4885CACNA1H 3/4885CACNA1G 1/4885 |
| US-11311522-B1 | Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | CACNA1G, CHRNA3, CACNA1H | CACNA1I 5/4885CACNA1H 3/4885CACNA1G 1/4885 |
| US-20220016095-A1 | TREATING ESSENTIAL TREMOR USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)ETHYL)ACETAMIDE | CACNA1G, CHRNA3, CACNA1H | CACNA1I 5/4885CACNA1H 3/4885CACNA1G 1/4885 |
| US-20230165847-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1H 2/4885CACNA1G 1/4885 |
| US-20230192674-A1 | SMALL MOLECULE INHIBITORS OF CAV3.2 ACTIVITY AND USES THEREOF | CACNA1B, CACNG3, CACNA1C | CACNA1I 7/4885CACNA1H 15/4885CACNA1G 11/4885 |
| US-20240182436-A1 | SUBSTITUTED SULFONAMIDE-CHROMAN COMPOUNDS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ARSA, SNCA, F12 | CACNA1I 226/4885CACNA1H 369/4885CACNA1G 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.